Stock listing
Frankfurt:TE1 Bio-Techne Corp Aktie
German listing (Frankfurt) of Bio-Techne Corp · home listing NASDAQ:TECH
Follow Bio-Techne Corp into a list and get an email when it puts out news.
Share price · FWB:TE1
€65.82 EUR -1.18 (-1.8%)
Close on Nov 20, 2026
- Day range
- €64.88 – €65.82 EURNov 20, 2026
- Volume
- 10 sharesNov 20, 2026
- Market cap
- €10.32B EURAt the close on Nov 20, 2026 · price × 156.8M shares outstanding
- 52-week range
- €36.52 – €65.82 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €165 EURMedian day 0 shares · 48 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TECH · Home | $72.67 USD | -0.08 (-0.1%) | 3,663,174 | $72.74 | $72.77 | $72.66 | $72.75 | Close on Nov 20, 2026 |
| B3:T1CH34 | 13.38 BRL | 0.00 (0.0%) | — | 13.38 | 13.38 | 13.38 | 13.38 | Close on Nov 19, 2026 |
| Frankfurt:TE1 | €65.82 EUR | -1.18 (-1.8%) | 10 | €64.88 | €65.82 | €64.88 | €67.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:TE1 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €64.91 | +1.585 | +2.5% | €65.03 | €65.04 | €64.25 | 0 | |
| €63.32 | -0.053 | -0.1% | €63.32 | €63.32 | €63.32 | 0 | |
| €63.38 | -1.139 | -1.8% | €63.38 | €63.38 | €63.38 | 0 | |
| €64.51 | -0.208 | -0.3% | €64.51 | €64.51 | €64.51 | 0 | |
| €64.72 | +0.867 | +1.4% | €64.76 | €64.76 | €64.45 | 0 | |
| €63.86 | -0.342 | -0.5% | €64.42 | €64.71 | €63.84 | 4 | |
| €64.20 | -1.275 | -1.9% | €64.20 | €64.20 | €64.20 | 0 | |
| €65.47 | +1.123 | +1.7% | €65.47 | €65.47 | €65.47 | 61 | |
| €64.35 | +0.032 | 0.0% | €64.35 | €64.35 | €64.35 | 0 | |
| €64.32 | -0.005 | 0.0% | €64.32 | €64.32 | €64.32 | 2 | |
| €64.32 | +1.458 | +2.3% | €64.11 | €64.44 | €64.08 | 4 | |
| €62.86 | -1.074 | -1.7% | €62.86 | €62.86 | €62.86 | 0 | |
| €63.94 | +0.453 | +0.7% | €63.94 | €63.94 | €63.94 | 0 | |
| €63.49 | -1.167 | -1.8% | €63.49 | €63.49 | €63.49 | 0 | |
| €64.65 | +0.818 | +1.3% | €64.66 | €64.67 | €64.65 | 0 | |
| €63.83 | +1.067 | +1.7% | €63.83 | €63.83 | €63.83 | 0 | |
| €62.77 | -1.021 | -1.6% | €62.77 | €62.77 | €62.77 | 0 | |
| €63.79 | +0.108 | +0.2% | €63.79 | €63.79 | €63.79 | 0 | |
| €63.68 | -1.233 | -1.9% | €63.68 | €63.68 | €63.68 | 0 | |
| €64.91 | +1.093 | +1.7% | €64.64 | €64.93 | €64.49 | 0 | |
| €63.82 | +0.36 | +0.6% | €63.82 | €63.82 | €63.82 | 0 | |
| €63.46 | -0.159 | -0.2% | €63.46 | €63.46 | €63.46 | 2 | |
| €63.62 | -0.066 | -0.1% | €63.62 | €63.62 | €63.62 | 0 | |
| €63.69 | -0.325 | -0.5% | €63.69 | €63.69 | €63.69 | 0 | |
| €64.01 | +0.101 | +0.2% | €64.21 | €64.22 | €63.62 | 0 | |
| €63.91 | -0.39 | -0.6% | €64.09 | €64.10 | €63.85 | 0 | |
| €64.30 | +0.889 | +1.4% | €64.30 | €64.30 | €64.30 | 0 | |
| €63.41 | +0.565 | +0.9% | €63.41 | €63.41 | €63.41 | 0 | |
| €62.85 | -0.647 | -1.0% | €62.85 | €62.85 | €62.85 | 0 | |
| €63.49 | +0.099 | +0.2% | €63.18 | €63.53 | €63.03 | 0 | |
| €63.39 | +0.016 | 0.0% | €63.91 | €63.93 | €63.31 | 1 | |
| €63.38 | +0.552 | +0.9% | €62.73 | €63.42 | €62.65 | 0 | |
| €62.83 | +0.434 | +0.7% | €63.21 | €63.28 | €62.58 | 0 | |
| €62.39 | -0.493 | -0.8% | €62.47 | €62.63 | €62.39 | 0 | |
| €62.88 | +0.44 | +0.7% | €63.25 | €63.39 | €62.63 | 0 | |
| €62.44 | -0.316 | -0.5% | €62.54 | €62.60 | €62.28 | 0 | |
| €62.76 | +0.793 | +1.3% | €62.88 | €62.88 | €62.29 | 0 | |
| €61.97 | -0.153 | -0.2% | €61.93 | €62.19 | €61.70 | 0 | |
| €62.12 | +0.705 | +1.1% | €61.96 | €62.28 | €61.86 | 0 | |
| €61.42 | -0.143 | -0.2% | €61.38 | €61.64 | €61.22 | 0 | |
| €61.56 | +0.302 | +0.5% | €61.75 | €61.81 | €61.56 | 62 | |
| €61.26 | -0.451 | -0.7% | €61.19 | €61.53 | €61.03 | 0 | |
| €61.71 | +0.127 | +0.2% | €61.83 | €61.91 | €61.07 | 0 | |
| €61.58 | -0.024 | 0.0% | €61.47 | €61.73 | €61.44 | 0 | |
| €61.60 | -0.725 | -1.2% | €62.00 | €62.00 | €61.19 | 0 | |
| €62.33 | +0.566 | +0.9% | €62.35 | €62.42 | €61.72 | 0 | |
| €61.76 | +0.148 | +0.2% | €61.76 | €61.76 | €61.76 | 0 | |
| €61.62 | +0.089 | +0.1% | €61.62 | €61.62 | €61.62 | 0 | |
| €61.53 | +0.293 | +0.5% | €61.53 | €61.53 | €61.53 | 0 | |
| €61.23 | -0.233 | -0.4% | €61.23 | €61.24 | €61.22 | 0 | |
| €61.47 | -0.228 | -0.4% | €61.51 | €61.51 | €61.47 | 0 | |
| €61.69 | +0.832 | +1.4% | €61.71 | €61.92 | €61.18 | 0 | |
| €60.86 | -0.717 | -1.2% | €60.86 | €60.86 | €60.86 | 0 | |
| €61.58 | -0.59 | -0.9% | €61.58 | €61.58 | €61.58 | 0 | |
| €62.17 | +0.936 | +1.5% | €61.17 | €62.81 | €61.03 | 10 | |
| €61.23 | -0.27 | -0.4% | €61.29 | €61.32 | €61.23 | 2 | |
| €61.50 | -0.185 | -0.3% | €61.50 | €61.50 | €61.50 | 0 |
Splits
1 split · FWB:TE1 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 4-for-1 | Split |
- Ticker
- Frankfurt:TE1
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
Bio-Techne declares dividend
Latest earnings call · May 6, 2026
Bio-Techne (NASDAQ:TECH) Q3 2026 Earnings Call
Replay and transcript
Latest deck · January 2026
Investor Presentation (January 2026)
Investor deck · 14 slides
Latest news
Bio-Techne declares dividend
Nov 3, 2026
Closed €63.38 (-1.8%) on Nov 4, 2026
Amendment to Annual Report (Form 10-K/A)
Oct 28, 2026
Closed €64.20 (-1.9%) on Oct 29, 2026
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
Oct 8, 2026
Closed €63.46 (-0.2%) on Oct 8, 2026
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
Sep 23, 2026
Closed €62.83 (+0.7%) on Sep 23, 2026
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Sep 22, 2026
Closed €62.39 (-0.8%) on Sep 22, 2026
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Sep 1, 2026
Closed €61.53 (+0.5%) on Sep 1, 2026
Bio-Techne Corrects Dividend Announcement
Aug 13, 2026
Closed €62.13 (-0.4%) on Aug 13, 2026
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
Aug 12, 2026
Closed €62.41 (+0.7%) on Aug 12, 2026
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
Jul 8, 2026
Closed €61.10 (+0.1%) on Jul 8, 2026
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
Jun 25, 2026
Closed €49.89 (+2.0%) on Jun 25, 2026
Bio-Techne Corp on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 30 in the last 12 months · 305 in all · newest Nov 4, 2026 · oldest 2019
- Calls
- 27 calls with a replay · 27 with a transcript · latest May 6, 2026
- Decks
- 16 decks · latest January 2026
Where Bio-Techne Corp is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TECH · Home listing | NASDAQ | United States | USD |
| gettex:TE1 | gettex | Germany | EUR |
| LS Exchange:A12ENG | LS Exchange | Germany | EUR |
| BIVA:TECH | BIVA | Mexico | MXN |
| B3:T1CH34 | B3 | Brazil | BRL |
| BMV:TECH | BMV | Mexico | MXN |
| Lang & Schwarz:A12ENG | Lang & Schwarz | Germany | EUR |
| Milan:1TECH | Milan | Italy | EUR |
| BOATS:TECH | BOATS | United States | USD |
| Stuttgart:TE1 | Stuttgart | Germany | EUR |
| Dusseldorf:TE1 | Dusseldorf | Germany | EUR |
| Tradegate:TE1 | Tradegate | Germany | EUR |
| Frankfurt:TE1 · This page | Frankfurt | Germany | EUR |
| Hamburg:TE1 | Hamburg | Germany | EUR |
| Munich:TE1 | Munich | Germany | EUR |
| Hanover:TE1 | Hanover | Germany | EUR |
| Xetra:TE1 | Xetra | Germany | EUR |
Valuation
P/E 66.4× against a median of 32.1×: 7th lowest of 8 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $11.35B USD
- P/E
- 66.4×
- EV/sales
- 9.2×
- EV/EBITDA
- 33.6×
- Price/book
- 5.3×
- Gross margin
- 65.8%
- Operating margin
- 19.6%
- Net margin
- 14.0%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.54
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Bio-Techne Corp · NASDAQ:TECH | US$11.41B | US$11.35B | 66.4× | 9.2× | 33.6× | 5.3× | 14.0% | 0.1× | 0.54 |
| Charles River Laboratories International, Inc. · NYSE:CRL | US$15.06B | US$14.86B | 375× | 3.7× | 33.5× | 4.7× | 1.0% | 0.0× | 1.23 |
| ICON plc · NASDAQ:ICLR | US$14.41B | US$16.98B | 32.1× | 2.1× | 15.7× | 1.6× | 5.5% | 0.4× | 1.08 |
| bioMerieux SA · EURONEXT:BIM | US$11.79B | US$11.53B | 27.0× | 2.6× | 10.9× | 2.5× | 9.8% | 0.1× | n/a |
| Qiagen N.V. · NYSE:QGEN | US$10.18B | US$11.03B | 24.9× | 5.3× | 15.0× | 3.0× | 19.5% | 0.5× | 0.33 |
| Avantor, Inc. · NYSE:AVTR | US$10.06B | US$13.28B | 29.8× | 2.0× | 14.7× | 1.7× | 5.1% | 0.6× | 0.78 |
| WuXi XDC Cayman, Inc. · HKEX:2268 | US$9.64B | US$8.87B | 43.4× | 9.9× | 33.4× | 5.7× | 24.9% | 0.1× | n/a |
| Tempus AI, Inc. · NASDAQ:TEM | US$9.58B | US$8.99B | n/a | 6.0× | n/a | 19.1× | −12.5% | 0.0× | 2.51 |
| Bruker Corporation · NASDAQ:BRKR | US$8.62B | US$10.22B | n/a | 2.9× | 64.4× | 3.7× | −3.5% | 0.7× | 1.72 |
| Pharmaron Beijing Co., Ltd. Class A · SZSE:300759 | US$8.54B | US$8.25B | 32.1× | 3.4× | n/a | 3.4× | 11.1% | 0.1× | n/a |
| GenScript Biotech Corporation · HKEX:1548 | US$8.08B | US$7.50B | n/a | 7.8× | 22.8× | 2.1× | −55.5% | 0.1× | n/a |
| Median of the others | US$9.85B | US$10.62B | 32.1× | 3.6× | 19.2× | 3.2× | 5.3% | 0.1× | 1.16 |
Forecasts
12 hold · 1 strong sell · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 70.50 USD · Analysts' mean
- EPS, year to Jun 2027
- 2.01 · 9 analysts
- Revenue, year to Jun 2027
- 1.27B · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Steve Crouse | President, Diagnostics and Spatial Biology Segment |
| David Clair | Vice President, Investor Relations |
Board
| Director | Role |
|---|---|
| Alpna Seth | Director |
| Amy E. Herr | Director |
| John L. Higgins | Director |
| Joseph D. Keegan | Director |
| Judith Klimovsky | Director |
| Julie L. Bushman | Director |
| Robert V. Baumgartner | Director |
| Rupert Vessey | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Bio-Techne (NASDAQ:TECH) Q3 2026 Earnings Call | Wed, May 06, 2026 · 9:00 AM ET | Replay |
| Bio-Techne (NASDAQ:TECH) Q2 2026 Earnings Call | Wed, Feb 04, 2026 · 9:00 AM ET | Replay |
| Bio-Techne (NASDAQ:TECH) Q1 2026 Earnings Call | Wed, Nov 05, 2025 · 9:00 AM ET | Replay |
| Bio-Techne (NASDAQ:TECH) Q4 2025 Earnings Call | Wed, Aug 06, 2025 · 9:00 AM ET | Replay |
| Bio-Techne (NASDAQ:TECH) Q3 2025 Earnings Call | Wed, May 07, 2025 · 9:00 AM ET | Replay |
| Bio-Techne (NASDAQ:TECH) Q2 2025 Earnings Call | Wed, Feb 05, 2025 · 9:00 AM ET | Replay |
| Bio-Techne (NASDAQ:TECH) Q1 2025 Earnings Call | Wed, Oct 30, 2024 · 9:00 AM ET | Replay |
| Bio-Techne (NASDAQ:TECH) Q4 2024 Earnings Call | Wed, Aug 07, 2024 · 9:00 AM ET | Replay |
| Bio-Techne (NASDAQ:TECH) Q3 2024 Earnings Call | Wed, May 01, 2024 · 8:00 AM ET | Replay |
| Bio-Techne (NASDAQ:TECH) Q2 2024 Earnings Call | Thu, Feb 01, 2024 · 9:00 AM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Nov 18, 2026 | +0.1% |
| Q4 2026 | Aug 12, 2026 · Before open | +0.1% |
| Q3 2026 | May 6, 2026 · Before open | −16.4% |
| Q2 2026 | Feb 4, 2026 · Before open | +6.3% |
| Q1 2026 | Nov 5, 2025 · Before open | −1.9% |
| Q4 2025 | Aug 6, 2025 · Before open | −8.7% |
| Q3 2025 | May 7, 2025 · Before open | +2.2% |
| Q2 2025 | Feb 5, 2025 · Before open | +3.7% |
| Q1 2025 | Oct 30, 2024 · Before open | +7.5% |
| Q4 2024 | Aug 7, 2024 · Before open | −9.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2024 | May 1, 2024 · Before open | +16.2% |
| Q2 2024 | Feb 1, 2024 · Before open | −2.5% |
| Q1 2024 | Oct 31, 2023 · Before open | −3.5% |
| Q4 2023 | Aug 8, 2023 · Before open | +3.7% |
| Q3 2023 | May 3, 2023 · Before open | +7.2% |
| Q2 2023 | Feb 2, 2023 · Before open | −0.5% |
| Q1 2023 | Nov 1, 2022 · Before open | +4.4% |
| Q4 2022 | Aug 4, 2022 · Before open | −0.2% |
| Q3 2022 | May 4, 2022 · Before open | +3.2% |
| Q2 2022 | Feb 1, 2022 · Before open | +6.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2026) | Investor deck | 14 slides | January 2026 |
| Investor Presentation (June 2025) | Investor deck | 15 slides | Jun 3, 2025 |
| Investor Presentation (January 2025) | Investor deck | 15 slides | Jan 14, 2025 |
| Investor Presentation (June 2024) | Investor deck | 26 slides | June 2024 |
| Investor Presentation (January 2024) | Investor deck | 26 slides | January 2024 |
| Investor Day (September 2023) | Investor day | 125 slides | Sep 8, 2023 |
| Investor Presentation (January 2023) | Investor deck | 29 slides | January 2023 |
| Investor Presentation (March 2022) | Investor deck | 27 slides | March 2022 |
| J.P. Morgan Healthcare Conference 2022 | Conference | 28 slides | January 2022 |
| Investor Presentation (June 2021) | Investor deck | 22 slides | June 2021 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| J.P. Morgan Healthcare Conference 2021 | Conference | 17 slides | January 2021 |
| Investor Presentation (May 2020) | Investor deck | 13 slides | May 2020 |
| Investor Presentation (November 2019) | Investor deck | 10 slides | November 2019 |
| Investor Day (September 2018) | Investor day | 123 slides | Sep 7, 2018 |
| Merger or Acquisition (June 2018) | Merger or acquisition | 18 slides | June 2018 |
| Investor Day (September 2016) | Investor day | 105 slides | Sep 15, 2016 |
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.22B | 1.22B | 1.16B | 1.14B | 1.11B | 931.0M | 738.7M | 714.0M | 643.0M | 563.0M |
| Cost of revenue | 416.0M | 429.4M | 389.3M | 366.9M | 349.1M | 298.2M | 255.5M | 240.5M | 210.8M | 188.5M |
| Gross profit | 799.1M | 790.3M | 769.7M | 769.8M | 756.5M | 632.9M | 483.2M | 473.5M | 432.1M | 374.5M |
| Research and development | 94.8M | 99.5M | 96.7M | 92.5M | 87.1M | 70.6M | 65.2M | 62.4M | 55.3M | 53.5M |
| Selling, general and administrative | 452.4M | 588.5M | 466.4M | 378.4M | 372.8M | 325.0M | 260.6M | 264.4M | 240.6M | 200.4M |
| Operating income | 251.9M | 102.3M | 206.7M | 298.9M | 296.6M | 237.3M | 157.4M | 146.7M | 136.2M | 120.6M |
| Depreciation and amortization | 97.4M | 109.9M | 111.7M | 107.2M | 101.1M | 87.7M | 82.7M | 78.2M | 64.5M | 60.0M |
| EBITDA | 349.2M | 212.2M | 318.4M | 406.2M | 397.7M | 325.0M | 240.2M | 224.9M | 200.6M | 180.6M |
| Interest expense | 9.63M | 8.51M | 15.7M | 11.2M | 11.3M | 14.0M | 19.2M | 21.7M | 10.2M | 7.36M |
| Income before tax | 240.7M | 98.5M | 185.7M | 338.7M | 301.4M | 148.2M | 276.5M | 112.0M | 126.0M | 112.0M |
| Income tax | 58.8M | 25.1M | 17.6M | 53.2M | 38.3M | 8.59M | 47.2M | 15.9M | -198.0K | 35.9M |
| Net income | 181.8M | 73.4M | 168.1M | 285.3M | 272.1M | 140.4M | 229.3M | 96.1M | 126.2M | 76.1M |
| Earnings per share, basic | 1.17 | 0.47 | 1.07 | 1.81 | 1.73 | 0.91 | 6.00 | 2.54 | 3.36 | 2.04 |
| Earnings per share, diluted | 1.16 | 0.46 | 1.05 | 1.76 | 1.66 | 0.87 | 5.82 | 2.47 | 3.31 | 2.03 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 264.7M | 162.2M | 151.8M | 180.6M | 172.6M | 199.1M | 146.6M | 100.9M | 122.0M | 91.6M |
| Short-term investments | 0 | 1.07M | 23.7M | 74.5M | 32.5M | 124.3M | 65.1M | 59.8M | 66.1M | |
| Receivables | 216.6M | 206.9M | 241.4M | 218.5M | 194.5M | 145.4M | 122.5M | 137.5M | 120.3M | 116.8M |
| Inventory | 195.7M | 189.4M | 179.7M | 171.6M | 141.1M | 116.7M | 103.2M | 91.0M | 85.6M | 85.6M |
| Current assets | 744.4M | 608.3M | 617.4M | 621.5M | 605.6M | 510.6M | 520.9M | 412.6M | 398.4M | 348.0M |
| Property, plant and equipment | 231.8M | 245.7M | 251.2M | 226.2M | 223.2M | 207.9M | 176.8M | 154.0M | 145.3M | 135.1M |
| Goodwill | 975.4M | 980.9M | 972.7M | 872.7M | 822.1M | 843.1M | 728.3M | 732.7M | 597.9M | 579.0M |
| Total assets | 2.59B | 2.56B | 2.70B | 2.64B | 2.29B | 2.26B | 2.03B | 1.88B | 1.59B | 1.56B |
| Accounts payable | 26.7M | 25.3M | 38.0M | 25.7M | 33.9M | 29.4M | 23.1M | 16.2M | 18.5M | 16.9M |
| Current liabilities | 163.7M | 175.8M | 159.4M | 128.5M | 176.0M | 152.3M | 106.7M | 102.0M | 79.5M | 135.5M |
| Long-term debt | 200.0M | 346.0M | 319.0M | 350.0M | 243.4M | 328.8M | 344.2M | 492.7M | 339.0M | 343.8M |
| Total debt | 289.1M | 444.1M | 419.5M | 455.0M | 12.5M | 12.5M | 12.5M | 12.5M | 347.9M | 349.9M |
| Total liabilities | 478.5M | 639.1M | 635.0M | 672.2M | 593.8M | 691.7M | 646.4M | 718.8M | 514.1M | 605.8M |
| Shareholders' equity | 2.11B | 1.92B | 2.07B | 1.97B | 1.70B | 1.56B | 1.38B | 1.17B | 1.08B | 949.6M |
| Shares outstanding | 156.1M | 155.0M | 158.2M | 157.6M | 156.6M | 39.0M | 38.5M | 37.9M | 37.6M | 37.4M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 292.1M | 287.6M | 299.0M | 254.4M | 325.3M | 352.2M | 205.2M | 181.6M | 170.4M | 143.7M |
| Capital spending | -28.9M | -31.0M | -62.9M | -38.2M | -44.9M | -44.3M | -51.7M | -25.4M | -20.9M | -15.2M |
| Free cash flow | 263.2M | 256.6M | 236.1M | 216.1M | 280.4M | 307.9M | 153.5M | 156.2M | 149.4M | 128.5M |
| Cash from investing | -18.2M | -35.2M | -203.0M | -265.6M | -96.9M | -243.5M | 27.1M | -336.8M | -38.7M | -306.0M |
| Cash from financing | -169.1M | -253.9M | -122.4M | 22.6M | -242.9M | -62.6M | -183.8M | 134.4M | -99.2M | 189.1M |
| Dividends paid | -49.9M | -50.4M | -50.4M | -50.3M | -50.2M | -49.6M | -48.9M | -48.4M | -48.0M | -47.3M |
| Share buybacks | -41.7M | -275.7M | -80.0M | -19.6M | -160.9M | -43.2M | -50.1M | -15.4M | 0 | 5.26M |
| Change in cash | 102.5M | 10.4M | -28.8M | 8.00M | -26.5M | 52.5M | 45.7M | -21.1M | 30.4M | 27.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q/A · Quarterly report, amended | Nov 12, 2026 | Quarterly report | SEC |
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 2, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 2, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 2, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 2, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 10-K/A · Annual report, amended | Oct 28, 2026 | Annual report | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 23, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Sep 14, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Sep 9, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Sep 2, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Aug 25, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Aug 24, 2026 | Annual report | SEC |
| DEFM14A | Aug 20, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| PREM14A | Aug 10, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jul 9, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 25, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Jun 25, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 25, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| SD · Specialized disclosure | Jun 1, 2026 | ESG report | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 11, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Feb 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 4, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Sep 19, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Sep 19, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 19, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 25, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 25, 2025 | Other filings | SEC |
| 10-K · Annual report | Aug 22, 2025 | Annual report | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 9, 2025 | Other filings | SEC |
| SD · Specialized disclosure | May 30, 2025 | ESG report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| 8-K · Current report | May 6, 2025 | Current report | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Feb 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 5, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 27, 2025 | Other filings | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 5, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 21, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Sep 12, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Sep 12, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 12, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 3, 2024 | Insider trade | SEC |
| 10-K · Annual report | Aug 22, 2024 | Annual report | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 8, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2024 | Insider trade | SEC |
| SD · Specialized disclosure | May 31, 2024 | ESG report | SEC |
| 4 · Change in ownership | May 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 14, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 6, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 3, 2024 | Insider trade | SEC |
| 8-K · Current report | May 1, 2024 | Results | SEC |
| 8-K · Current report | Apr 30, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Apr 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 7, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 7, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 1, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 24, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 21, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 14, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 14, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 14, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 14, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 9, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 31, 2023 | Results | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Bio-Techne Corp’s releases · as of Oct 9, 2026
- Common shares
- 157,055,564
- Fully diluted
- 157,055,564
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 157,055,564 | Oct 9, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 9, 2026 | 157,055,564 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John Higgins Other companies: Immunome, Inc. (Chief Scientific Officer · Since at least Oct 2, 2023); OmniAb, Inc. (Board Chair · Since at least Nov 1, 2022); Ligand Pharmaceuticals Incorporated (Director · May 14, 2019 – Dec 28, 2022 · Past) | Director · Since at least Jun 4, 2019 |
| Julie L. Bushman Other companies: Phillips 66 (Director · Since at least Jul 8, 2020); Adient plc (Board Member · Since at least Oct 31, 2016); 3M Company (Executive Vice President · Jun 1, 2011 – Feb 4, 2020 · Past) | Director · Since at least Aug 3, 2020 |
| Alpna Seth Other companies: Keros Therapeutics, Inc. (Director · Since at least May 1, 2023); Seagen Inc (Director · Mar 15, 2018 – Dec 14, 2023 · Past) | Director · Since at least Oct 26, 2017 |
| Joseph D. Keegan Other companies: Interpace Biosciences, Inc. (Director · Since at least Jan 1, 2016); Stereotaxis, Inc. (Director · Feb 16, 2011 – May 24, 2016 · Past) | Director · Since at least Oct 26, 2017 |
| Randolph C Steer Other companies: Immunic, Inc. (Director · Apr 16, 2014 – May 23, 2017 · Past); Capstone Holding Corp. (President · Jan 17, 2011 – Jan 17, 2011 · Past) | Director · Oct 28, 2010 – Oct 26, 2023 · Past |
| Rupert Vessey Other companies: Generate Biomedicines, Inc. (Director · Since at least Feb 26, 2026); Bristol-Myers Squibb Company (EVP & President, Research · Oct 30, 2020 – May 3, 2023 · Past) | Director · Since at least Oct 29, 2020 |
| Brenda S Furlow Other companies: TomoTherapy Inc (VP, General Counsel & Secr. · Aug 25, 2008 – Jun 10, 2011 · Past) | SVP - GENERAL COUNSEL · Aug 4, 2014 – Dec 7, 2022 · Past |
| Gregory J Melsen Other companies: Janel Corp. (Director · Since at least Jan 2, 2018) | CFO · Jul 27, 2006 – Aug 1, 2013 · Past |
| Harold J Wiens Other companies: 3M Company (EXEC VP TRANSPORTATION · Dec 31, 2005 – Dec 31, 2005 · Past) | Director · May 15, 2014 – May 22, 2020 · Past |
| Judith Klimovsky Other companies: Bellicum Pharmaceuticals Inc (Director · Dec 20, 2018 – Jan 3, 2023 · Past) | Director · Since at least Apr 24, 2024 |
All 30 people
| Person | Seat |
|---|---|
| Kim Kelderman Other companies: CONMED Corporation (Director · Since at least Sep 8, 2025) | Chief Executive Officer, Director · Since at least Apr 30, 2018 |
| Matthew McManus Other companies: Azenta, Inc. (EVP & Chief Operating Officer · Jan 24, 2022 – Aug 19, 2022 · Past) | President - Diag & Spatial Bio · Since at least Jan 8, 2024 |
| Norman David Eansor Other companies: Marker Therapeutics, Inc. (Director · Since at least May 9, 2019) | President-Protein Sciences · Jun 12, 2019 – Nov 12, 2021 · Past |
| Roger C Lucas Other companies: ChemoCentryx Inc. (Director · Feb 8, 2012 – Mar 5, 2019 · Past) | Director · Feb 1, 2006 – Oct 10, 2017 · Past |
| Steven C Crouse Other companies: OmniAb, Inc. (Director · Since at least Apr 21, 2025) | President - Diag & Spatial Bi · Since at least Mar 1, 2026 |
| Amy E. Herr | Director · Since at least Feb 1, 2025 |
| Charles A Dinarello | Director · Oct 26, 2017 – Aug 8, 2018 · Past |
| David Clair | Vice President, Investor Relations · Since at least Nov 4, 2026 |
| Howard V Oconnell | Director · Feb 13, 2006 – Feb 19, 2015 · Past |
| James Hippel | CFO · Since at least Apr 1, 2014 |
| J Fernando Bazan | Chief Technical Officer · Aug 1, 2013 – Oct 26, 2017 · Past |
| Kevin J Reagan | Senior VP - Biotech · Aug 1, 2013 – Dec 5, 2014 · Past |
| Monica Tsang | VP of Research · Feb 27, 2006 – May 3, 2007 · Past |
| Robert M Gavin | Sen. VP Protein Platforms · Nov 25, 2014 – Oct 26, 2017 · Past |
| Robert V. Baumgartner | Director · Since at least Feb 3, 2006 |
| Roeland Nusse | Director · Since at least May 26, 2010 |
| Shane Bohnen | SVP - General Counsel · Since at least Mar 3, 2023 |
| Steve Crouse | President, Diagnostics and Spatial Biology Segment · Since at least Feb 11, 2026 |
| Thomas E Oland | CEO, President, Director · Jan 31, 2006 – Nov 30, 2011 · Past |
| William Geist | PRESIDENT, PROTEIN SCIENCES · Since at least Aug 15, 2025 |
Log in to ask 6ix AI your own questions about Bio-Techne Corp.